Manuel Sequeira
Overview
Explore the profile of Manuel Sequeira including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
448
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
London C, Acquaviva J, Smith D, Sequeira M, Ogawa L, Gardner H, et al.
Clin Cancer Res
. 2018 Sep;
24(24):6396-6407.
PMID: 30171047
Purpose: STA-1474, prodrug of the heat shock protein 90 inhibitor (HSP90i) ganetespib, previously demonstrated activity in canine preclinical models of cancer; interestingly, prolonged infusions were associated with improved biologic activity....
2.
Proia D, Smith D, Zhang J, Jimenez J, Sang J, Ogawa L, et al.
Mol Cancer Ther
. 2015 Aug;
14(11):2422-32.
PMID: 26271675
The clinical benefits of chemotherapy are commonly offset by insufficient drug exposures, narrow safety margins, and/or systemic toxicities. Over recent decades, a number of conjugate-based targeting approaches designed to overcome...
3.
Smith D, Acquaviva J, Sequeira M, Jimenez J, Zhang C, Sang J, et al.
Target Oncol
. 2014 Aug;
10(2):235-45.
PMID: 25077897
Small molecule inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity, such as erlotinib and gefitinib, revolutionized therapy for non-small cell lung cancer (NSCLC) patients whose tumors harbor activating...
4.
Acquaviva J, He S, Zhang C, Jimenez J, Nagai M, Sang J, et al.
Mol Cancer Res
. 2014 May;
12(7):1042-54.
PMID: 24784839
Unlabelled: Activating mutations and/or overexpression of FGFR3 are common in bladder cancer, making FGFR3 an attractive therapeutic target in this disease. In addition, FGFR3 gene rearrangements have recently been described...
5.
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
He S, Smith D, Sequeira M, Sang J, Bates R, Proia D
Invest New Drugs
. 2014 Apr;
32(4):577-86.
PMID: 24682747
The integration of targeted agents to standard cytotoxic regimens has improved outcomes for patients with colorectal cancer (CRC) over recent years; however this malignancy remains the second leading cause of...
6.
Acquaviva J, He S, Sang J, Smith D, Sequeira M, Zhang C, et al.
Mol Cancer Res
. 2014 Feb;
12(5):703-13.
PMID: 24554781
Unlabelled: Because of their pleiotropic effects on critical oncoproteins, inhibitors of HSP90 represent a promising new class of therapeutic agents for the treatment of human cancer. However, pharmacologic inactivation of...
7.
Acquaviva J, Smith D, Jimenez J, Zhang C, Sequeira M, He S, et al.
Mol Cancer Ther
. 2014 Jan;
13(2):353-63.
PMID: 24398428
Activating BRAF kinase mutations serve as oncogenic drivers in over half of all melanomas, a feature that has been exploited in the development of new molecularly targeted approaches to treat...
8.
Proia D, Zhang C, Sequeira M, Jimenez J, He S, Spector N, et al.
Clin Cancer Res
. 2013 Nov;
20(2):413-24.
PMID: 24173541
Purpose: Treatment options for patients with triple-negative breast cancer (TNBC) are largely limited to systemic chemotherapies, which have shown disappointing efficacy in the metastatic setting. Here, we undertook a comprehensive...
9.
Sang J, Acquaviva J, Friedland J, Smith D, Sequeira M, Zhang C, et al.
Cancer Discov
. 2013 Mar;
3(4):430-43.
PMID: 23533265
Unlabelled: EML4-ALK gene rearrangements define a unique subset of patients with non-small cell lung carcinoma (NSCLC), and the clinical success of the anaplastic lymphoma kinase (ALK) inhibitor crizotinib in this...
10.
He S, Zhang C, Shafi A, Sequeira M, Acquaviva J, Friedland J, et al.
Int J Oncol
. 2012 Nov;
42(1):35-43.
PMID: 23152004
Androgen ablation therapy represents the first line of therapeutic intervention in men with advanced or recurrent prostate tumors. However, the incomplete efficacy and lack of durable response to this clinical...